FIBROMYALGIA IS THE STRONGEST NEGATIVE PREDICTOR FOR THE ACHIEVEMENT OF EITHER REMISSION AND MINIMAL DISEASE ACTIVITY IN NAIVE PSORIATIC ARTHRITIS PATIENTS STARTING BIOLOGIC DRUGS

被引：3
|
作者：
Iannone, Florenzo [1 ]
Nivuori, Mariangela [1 ]
Lopalco, Giuseppe [1 ]
Anelli, Maria Grazia [1 ]
Coladonato, Laura [1 ]
Laselva, Gaetana [1 ]
Scioscia, Crescenzio [1 ]
机构：
[1] DETO, Rheumatol, Bari, Italy
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷
关键词：
D O I：
10.1136/annrheumdis-2019-eular.2220
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0380
引用
收藏
页码：1274 / 1274
页数：1
相关论文
共 50 条
  • [1] Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs
    Perrotta, Fabio Massimo
    Marchesoni, Antonio
    Lubrano, Ennio
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (02) : 350 - 355
  • [2] Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis
    Iannone, Florenzo
    Nivuori, Mariangela
    Fornaro, Marco
    Venerito, Vincenzo
    Cacciapaglia, Fabio
    Lopalco, Giuseppe
    RHEUMATOLOGY, 2020, 59 (07) : 1599 - 1606
  • [3] Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers
    Di Minno, Matteo Nicola Dario
    Peluso, Rosario
    Iervolino, Salvatore
    Russolillo, Anna
    Lupoli, Roberta
    Scarpa, Raffaele
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (06) : 1157 - 1162
  • [4] IS DISEASE DURATION AN INDEPENDENT PREDICTOR OF LOW DISEASE ACTIVITY/REMISSION AMONG BIOLOGIC-NAIVE PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH ABATACEPT?
    Harrold, L. R.
    Litman, H. J.
    Connolly, S. E.
    Kelly, S.
    Hua, W.
    Alemao, E.
    Rosenblatt, L.
    Rebello, S.
    Kremer, J. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 970 - 970
  • [5] OBESITY AND LOWER LIKELIHOOD OF ACHIEVING MINIMAL DISEASE ACTIVITY AND REMISSION IN PSORIATIC ARTHRITIS PATIENTS
    Vallejo-Yague, E.
    Burkard, T.
    Moeller, B.
    Burden, A. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 860 - 860
  • [6] DOMAINS CONTRIBUTING TO MINIMAL DISEASE ACTIVITY ACHIEVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING GUSELKUMAB
    Coates, L.
    Rahman, P.
    Mease, P. J.
    Shawi, M.
    Rampakakis, E.
    Kollmeier, A.
    Xu, X. L.
    Chakravarty, S. D.
    Mcinnes, I.
    Tam, L. S.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 856 - 857
  • [7] Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
    Kavanaugh, Arthur
    Singh, Rakesh
    Karki, Chitra
    Etzel, Carol J.
    Kremer, Joel M.
    Greenberg, Jeffrey D.
    Griffith, Jenny
    CLINICAL RHEUMATOLOGY, 2018, 37 (08) : 2275 - 2280
  • [8] Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
    Arthur Kavanaugh
    Rakesh Singh
    Chitra Karki
    Carol J. Etzel
    Joel M. Kremer
    Jeffrey D. Greenberg
    Jenny Griffith
    Clinical Rheumatology, 2018, 37 : 2275 - 2280
  • [9] DEFINITION OF REMISSION AND MINIMAL DISEASE ACTIVITY IN PSORIATIC ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW
    Gudu, T.
    Ionescu, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 767 - 767
  • [10] THE PREVALENCE OF REMISSION IN A REAL-LIFE COHORT OF PSORIATIC ARTHRITIS PATIENTS TREATED WITH SYNTHETIC OR BIOLOGIC DISEASE MODIFYING DRUGS
    Favalli, E. G.
    Fassio, A.
    Bugatti, S.
    Batticciotto, A.
    Quartuccio, L.
    Filippini, M.
    Parisi, S.
    Biggioggero, M.
    Zanframundo, G.
    Giovannini, I.
    Ditto, M. G.
    Idolazzi, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 362 - 362
12345